Singapore-based biotechnology company uses Oracle AI Database and Oracle Cloud Infrastructure Enterprise AI to scale clinical knowledge delivery, help improve clinician productivity, and accelerate early disease detection
Oracle AI World Tour, Singapore — April 14, 2026 — Mirxes, the only publicly-listed molecular cancer early detection company in Asia Pacific, has developed an AI assistant for clinicians using Oracle AI Database and Oracle Cloud Infrastructure (OCI) Enterprise AI. The AI assistant, supported by specialised AI agents, enhances clinician productivity by delivering faster responses to scientific and product inquiries, effectively reducing response times during the pilot phase, with the goal of improving patient outcomes.
Following its milestone as Singapore’s first biotech unicorn in 2025, Mirxes is advancing its innovation journey by leveraging Oracle AI Database and OCI Enterprise AI to support growing demand for its microRNA-based early cancer detection solutions. As adoption of offerings, such as GASTROClear, expands into new markets, manual query handling began to slow knowledge delivery, creating inconsistencies, and diverting specialised clinical resources away from higher-value work. To address this, Mirxes developed an AI-powered knowledge assistant with agentic capabilities using Oracle AI Database and OCI Enterprise AI. Grounded in curated medical literature, scientific findings, and product documentation, the assistant delivers accurate, on-demand insights to clinicians at scale, while autonomously routing potential product-related inquiries and feedback to the relevant commercial teams for streamlined support. Clinical judgment and decision-making authority remains fully with the clinician, and the solution is designed with data privacy and regulatory compliance at its core, ensuring AI is deployed responsibly within a regulated healthcare environment.
“Earlier cancer detection depends on precision, speed, and trust in the information clinicians receive,” said Dr Zhou Lihan, co-founder and chief executive officer, Mirxes. “The science behind microRNA-based diagnostics is complex, and clinicians field many questions. By giving them fast access to accurate, up-to-date information, we can reduce that burden and allow them to redirect their time and expertise where it matters most – direct patient care. By working with Oracle to make our clinical and product knowledge more accessible – and deliver it consistently across clinicians and markets – the Mirxes team can focus on innovation and the expansion of cancer early detection.”
Mirxes closely collaborated with the Oracle AI Customer Excellence Center to develop and pilot its AI assistant for clinicians. The Oracle AI Customer Excellence Center provided the cloud and AI infrastructure support to help lay the groundwork for scalable deployment. Using Oracle AI Database to store Mirxes’ extensive product documentation, the AI assistant applies semantic search to identify the most up-to-date information and deliver relevant and precise answers in near real time. Using retrieval-augmented generation (RAG), the AI assistant interprets clinician questions and uses Oracle AI Database’s vector search to retrieve contextually relevant information to help ground responses.
“Healthcare and life sciences organizations need to quickly deliver accurate, consistent information to clinicians across complex, rapidly evolving datasets,” said Chin Ying Loong, senior vice president and regional managing director, ASEAN & SAGE, Oracle. “Working with the Oracle AI Customer Excellence Center in Singapore, Mirxes was able to draw on Oracle’s regional AI specialists and OCI resources to pilot and refine its AI agent for clinicians. Built on Oracle AI Database and OCI Enterprise AI, this foundation helps enable Mirxes to scale trusted clinical knowledge delivery, enhance clinician efficiency, and support broader access to early cancer detection to improve patient outcomes.”
